Combatting Opioid Use

Combatting Opioid Use

Stimwave Expands Nationwide as Demand Booms for Wireless Device Options to Combat Opioid Use

POMPANO BEACH, Fla.–(BUSINESS WIRE)–Stimwave LLC, a medical device manufacturer and independent research institute headquartered in South Florida, has announced the expansion of their U.S. commercialization efforts for its neuromodulation devices. As many as 75 new positions will be created to increase sales and clinical support initiatives throughout the country. The expansion of Stimwave’s commercialization initiatives is in response to an increasing demand for its Freedom Spinal Cord Stimulation (SCS) System and StimQ Peripheral Nerve Stimulator (PNS) System, both utilizing its Wireless Pain Relief® technology as an alternative to opioids for chronic pain management.

“Our mission is to create innovative, wireless, minimally-invasive medical technology to revolutionize neuromodulation as we aim to improve the lives of patients with a cost-effective approach to pain management,” said Ms. Laura Tyler Perryman, the chairman and CEO of Stimwave. “The Stimwave team is on a journey to innovate and engineer new technology that has never been done before, which is a leap forward for medical science. We are extremely grateful for the market acceptance of our innovations and pleased to grow our support infrastructure to support that demand effectively.”

The augmented sales and clinical team will be tasked with bringing Stimwave’s Wireless Pain Relief® system to the more than 400 million patients worldwide who suffer from chronic pain. The expansion will allow Stimwave greater market penetration and coverage for physicians and patients demanding more freedom in therapy options. A variety of support positions will also be implemented to enhance the overall patient experience. Creating an integrated team approach to customer service at the field level will provide clinical office support and patient care with the goal to offer the best in the industry.

The expanded team will complement the existing group of Stimwave’s experienced SCS and PNS therapy specialists. Stimwave’s commitment to providing support for both customer and patient care has been demonstrated in their focus on developing a clinical sales team comprised of proficient, clinically trained pain nurses and SCS/PNS industry sales professionals.

With platform versatility that provides a unique and patient-specific approach to conventional SCS systems, Stimwave is establishing itself as a wireless alternative to the limited therapies currently available in conventional SCS systems. With an array of commercial activity in 2017 centered on the approvals of platform performance enhancements, the announcement of this staffing expansion reflects the subsequent demand created by these enhancements, many of which are unavailable with competitive conventional SCS systems. With conditional MRI full-body scan FDA clearances for both SCS and PNS devices, Stimwave has addressed a clinical need the industry has demanded for years and has not yet been made available through conventional SCS companies.